Research progress of neoadjuvant hormonal therapy for breast cancer

金恺睿; 俞晓立

doi:10.19401/j.cnki.1007-3639.2018.07.011

您当前的位置：

首页 >

文章列表页 >

Research progress of neoadjuvant hormonal therapy for breast cancer

更新时间：2026-01-27

- Research progress of neoadjuvant hormonal therapy for breast cancer
- China Oncology Vol. 28, Issue 7, Pages: 538-544(2018)
- 作者机构：
  
  复旦大学附属肿瘤医院放疗科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.07.011
  CLC： R737.9
- Published Online：10 August 2018，
  
  Published：10 August 2018
- 稿件说明：
移动端阅览
金恺睿,俞晓立. 乳腺癌新辅助内分泌治疗的研究进展[J]. 中国癌症杂志, 2018, 28(7): 538-544.

金恺睿, 俞晓立. Research progress of neoadjuvant hormonal therapy for breast cancer[J]. China Oncology, 2018, 28(7): 538-544.
金恺睿,俞晓立. 乳腺癌新辅助内分泌治疗的研究进展[J]. 中国癌症杂志, 2018, 28(7): 538-544. DOI： 10.19401/j.cnki.1007-3639.2018.07.011.

金恺睿, 俞晓立. Research progress of neoadjuvant hormonal therapy for breast cancer[J]. China Oncology, 2018, 28(7): 538-544. DOI： 10.19401/j.cnki.1007-3639.2018.07.011.

摘要

新辅助内分泌治疗作为新辅助化疗的一种安全有效的替代和补充，正被越来越多地应用于激素受体阳性的局部晚期乳腺癌患者中。但新辅助内分泌治疗在适应患者的筛选、疗效、预后的评判及治疗规范等方面仍存在诸多争议。现从新辅助内分泌治疗与新辅助化疗的比较、不同新辅助内分泌药物的比较、新辅助内分泌治疗的疗程、新辅助内分泌治疗联合化疗或靶向药物、新辅助内分泌治疗疗效、预后的评判及新辅助内分泌治疗后的辅助放疗指征等方面总结新辅助内分泌治疗的现状和进展。

Abstract

As a safe and effective substitute and supplement of neoadjuvant chemotherapy (NCT)

neoadjuvant hormonal therapy (NHT) has been increasingly used in patients with locally advanced breast cancer whose hormone receptors are positive. However

there are many controversies of NHT in the standard treatment

indications and assessment of the treatment effects. To review the current situation and research progress of NHT

this article discusses the following aspects: comparison of NCT and NHT

comparison of different NHT treatments

duration of NHT

combination of NHT and other neoadjuvant treatments

predictors of response and prognosis

and adjuvant radiation indications after NHT.

关键词

Keywords

references

Views

3485

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14

Axillary management after neoadjuvant therapy for breast cancer and optimization of sentinel lymph node diagnosis and treatment

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

Department of Laboratory Medicine, Xingtai People’s Hospital

AI问答

⁰